Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma

Journal of Immunological Methods

Volumn 345, Issue 1-2, 2009, Pages 106-111

  Jamieson, David ^a   Cresti, Nicola ^a   Verrill, Mark W ^b   Boddy, Alan V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Cell based ELISA; Herceptin; Pharmacokinetics; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 65649146104     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.04.006     Document Type: Article

References (23)

1. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson C., and Norton L. Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast. Journal of Clinical Oncology 14 (1996) 737
2. Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., Green M., Harvey V., Morales S., Barton C., and Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. Journal of Clinical Oncology 23 (2005) 2162
3. Baselga J., Perez E.A., Pienkowski T., and Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 11 (2006) 4
4. Botha J.L., Bray F., Sankila R., and Parkin D.M. Breast cancer incidence and mortality trends in 16 European countries. European Journal of Cancer 39 (2003) 1718
5. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756
6. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., and Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 17 (1999) 2639
7. Cooley S., Burns L.J., Repka T., and Miller J.S. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Experimental Hematology 27 (1999) 1533
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351 (1998) 1451
9. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology 18 (2007) 581
10. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., and Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. Journal of Clinical Oncology 21 (2003) 3965
11. Maple L., Lathrop R., Bozich S., Harman W., Tacey R., Kelley M., and Danilkovitch-Miagkova A. Development and validation of ELISA for Herceptin detection in human serum. Journal of Immunological Methods 295 (2004) 169
12. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Chan S., Grimes D., Anton A., Lluch A., Kennedy J., O'Byrne K., Conte P., Green M., Ward C., Mayne K., and Extra J.M. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 23 (2005) 4265
13. Pegram M.D., Lipton A., Hayes D.F., Weber B.L., Baselga J.M., Tripathy D., Baly D., Baughman S.A., Twaddell T., Glaspy J.A., and Slamon D.J. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. Journal of Clinical Oncology 16 (1998) 2659
14. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D., and Team H.T.S. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 353 (2005) 1659
15. Romond E.H., Perez E.A., Bryant J., Suman J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., and Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353 (2005) 1673
16. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Pawlicki M., Chan A., Smylie M., Liu M., Falkson C., Pinter T., Fornander T., Shiftan T., Valero V., Von Minckwitz G., Mackey J., Tabah-Fisch J., Buyse M., Lindsay M.A., Riva A., Bee V., Pegram M., Press M., and Crown J. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: 28th Annual San Antonio Breast Cancer Symposium (2005), Springer, San Antonio, TX S5
17. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human-breast cancer - correlation of relapse and survival with amplification of the her-2 neu oncogene. Science 235 (1987) 177
18. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344 (2001) 783
19. Tokuda Y., Watanabe T., Omuro Y., Ando M., Katsumata N., Okumura A., Ohta M., Fujii H., Sasaki Y., Niwa T., and Tajima T. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. British Journal of Cancer 81 (1999) 1419
20. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., and Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20 (2002) 719
21. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. Journal of Biological Chemistry 274 (1999) 8865
22. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., and Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Research 62 (2002) 4132
23. Yang X.Y., Chen E., Jiang H.G., Hartmann W.K., Mitra G., Hecht T., and Soman G. Development of a quantitative cell-based ELISA, for a humanized anti-IL-2/IL-15 receptor beta antibody (HuMik beta(1)), and correlation with functional activity using an antigen-transfected murine cell line. Journal of Immunological Methods 311 (2006) 71